Article Impact Level: HIGH Data Quality: STRONG Summary of the Journal of the American College of Cardiology, 81(4), 358–370. https://doi.org/10.1016/j.jacc.2022.10.036 Dr. Serdar Farhan et al
Points
- There are no publications with sufficient sample sizes to evaluate significant medical outcomes between bypass surgery and endovascular therapy for symptomatic femoropopliteal peripheral artery disease.
- According to these results, endovascular therapy provides a secure and reliable substitute for bypass surgery for people experiencing symptomatic femoropopliteal peripheral artery disease. The optimum revascularization techniques for these individuals can be further honed through upcoming research studies.
Summary
The survey examined the medical outcomes and related factors in patients experiencing femoropopliteal artery disease who underwent bypass surgery and endovascular therapy. In order to compare endovascular therapy with bypass surgery, all randomized controlled trials and patient records were combined for evaluation.
Five of the six randomized controlled trials that were currently accessible had consented to aggregate the individual patient records. The main objectives were significant adverse limb occurrences, a mix of all-cause mortality, significant amputation, or target limb intervention. Amputation-free life, significant adverse limb event components, and major catheterization were secondary goals. Early problems included hemorrhage, infections, or death from any cause in less than 30 days.
A total of 639 patients were examined. Their average age was 68.1 9.1 years, and 29.0% were female. Among categories, significant reliability coefficients were identical. Except for principal catheterization, this was lesser in patients who were given endovascular therapy than those who had undergone bypass. There were no significant differences across patients who were provided endovascular therapy and those who got bypass surgery at two years in terms of detrimental upper extremity occurrences, surgical excision life, reduced hospital stays, and considerably reduced incidence of exposure vulnerabilities were both related to endovascular therapy.
These results provide additional evidence for the effectiveness and security of endovascular therapy as a bypass surgery substitute in individuals with symptomatic femoropopliteal peripheral artery disorder.
Information about the heart disease risk factors, comorbidities, and death rates linked to revascularization techniques has been described. Still, statistics about the effects of specific susceptibility genes and pharmaceutical treatment on the basic catheterization of the goal abscess, health outcomes, and upper extremity operation are contradictory. A sizable, prospective, randomized investigation must be conducted to discover extra.
Link to the article: https://www.jacc.org/doi/10.1016/j.jacc.2022.10.036
References Farhan, S., Enzmann, F. K., Bjorkman, P., Kamran, H., Zhang, Z., Sartori, S., Vogel, B., Tarricone, A., Linni, K., Venermo, M., Van Der Veen, D., Moussalli, H., Mehran, R., Reijnen, M. M. P. J., Bosiers, M., & Krishnan, P. (2023). Revascularization Strategies for Patients With Femoropopliteal Peripheral Artery Disease. Journal of the American College of Cardiology, 81(4), 358–370. https://doi.org/10.1016/j.jacc.2022.10.036
